Niagen Bioscience Inc (NAGE) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Niagen Bioscience Inc

    NASDAQ: NAGE · Real-Time Price · USD
    6.93
    -0.45 (-6.10%)
    At close: Oct 03, 2025, 3:59 PM
    6.86
    -1.01%
    After-hours: Oct 03, 2025, 07:56 PM EDT

    Niagen Bioscience Inc Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 99.6M 83.57M 72.05M 67.45M
    Cost of Revenue
    		 38.01M 32.79M 29.25M 25.96M
    Gross Profit
    		 61.59M 50.78M 42.8M 41.49M
    Operating Income
    		 7.73M -5.6M -18.63M -27.07M
    Interest Income
    		 1.13M 661K 3K n/a
    Pretax Income
    		 8.86M -4.94M -16.54M -27.13M
    Net Income
    		 8.55M -4.94M -16.54M -27.13M
    Selling & General & Admin
    		 47.84M 51.42M 56.6M 64.73M
    Research & Development
    		 6.02M 4.96M 4.83M 3.83M
    Other Expenses
    		 n/a n/a n/a n/a
    Operating Expenses
    		 53.86M 56.38M 61.42M 68.56M
    Interest Expense
    		 n/a n/a n/a 55K
    Selling & Marketing Expenses
    		 29.47M 26.44M 28.31M 28.35M
    Cost & Expenses
    		 91.87M 89.17M 90.68M 94.52M
    Income Tax Expense
    		 305K n/a n/a n/a
    Shares Outstanding (Basic)
    		 85.42M 70.54M 68.92M 67.19M
    Shares Outstanding (Diluted)
    		 79.72M 74.98M 69.73M 67.19M
    EPS (Basic)
    		 0.10 -0.07 -0.24 -0.4
    EPS (Diluted)
    		 0.11 -0.07 -0.24 -0.4
    EBITDA
    		 9.21M -3.89M -16.74M -25.45M
    EBIT
    		 7.73M -5.6M -18.63M -27.07M
    Depreciation & Amortization
    		 1.48M 1.71M 1.88M 1.63M

    Add to Watchlist